Work

A phase 1, first-in-human, dose escalation and expansion study to evaluate the safety and tolerability of XmAb541 (claudin-6 x CD3) T-cell engaging bispecific antibody in subjects with germ cell tumors and other advanced solid tumors.

Year: 2025

Type: article

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.5_suppl.tps652

Authors: David Levitz, Martin Gutierrez, Ira Seth Winer, Matthew Reilley, Linda R. Duska, Vivek Subbiah, Debra L. Richardson, Chet Bohac, MICHAEL CHIARELLA, Carlos Naranjo, Jitendra Kanodia, Jacky Woo, Nicole Nevadunsky

Institutions: Albert Einstein College of Medicine, Montefiore Medical Center, Montefiore Einstein Comprehensive Cancer Center, Hackensack University Medical Center, Wayne State University, The Barbara Ann Karmanos Cancer Institute, University of Virginia Cancer Center, Sarah Cannon, OU Health Stephenson Cancer Center, University of Oklahoma Health Sciences Center

Language: English

Topic: Monoclonal and Polyclonal Antibodies Research

Subfield: Radiology, Nuclear Medicine and Imaging

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Xencor

OpenAlex ID: W4407700544

FWCI: 3.257

Cites:

Cited by: 6

Related to: 10